The preliminary closing of the European STOXX 600 Index fell by 0.12% to 636.35 points, marking the second consecutive trading day below its historical closing high, with a weekly gain of approximately 0.5%.

09:15 AM EDT, 10/06/2026 (MT Newswires) -- Consumer stocks were edging higher premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) up 0.1% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advancing by 0.4%. Nomad Foods (NOMD) stock was up nearly 3% after the company said it now expects fiscal 2026 organic revenue to decline 2% to 3%, compared with its previous guidance for a decline of 2% to 5%. PepsiCo (PEP) and Monster Beverage (MNST) can continue to label their cans in India as energy drinks after a court ruling, Reuters reported, citing a lawyer present at the hearing. PepsiCo shares were slightly higher and Monster Beverage stock was down 0.3% pre-bell. B&G Foods (BGS) said it cancelled its agreement to sell Green Giant Canada to Nortera Foods on Monday, after failing to obtain Canadian regulatory approval. Shares of B&G Foods were up more than 1% premarket.

09:04 AM EDT, 10/06/2026 (MT Newswires) -- (Updates with pricing details in the headline and the first paragraph; and the offering close date in the last paragraph.) TORM (TRMD) said Tuesday that OCM Njord, a company indirectly owned by funds managed by Oaktree Capital Management and its affiliates, priced a secondary offering of 6.3 million class A shares for gross proceeds of about $253.5 million. The company said OCM Njord owns about 6% of its class A shares before the offering. TORM is not selling any shares and will not receive proceeds from the offering, the company said. The offering is expected to close on Wednesday, TORM said.

NexPoint Residential Trust schedules a third-quarter 2026 earnings conference call for Nov. 3, 2026 at 11:00 a.m. ET. Third-quarter 2026 results release set for before the market open on Nov. 3, 2026. Live webcast planned on https://nxrt.nexpoint.com; replay expected to remain available for 60 days. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NexPoint Residential Trust Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060900PR_NEWS_USPR_____NY63815) on October 06, 2026, and is solely responsible for the information contained therein.

Sneha S K, Reuters, October 6 - Pharmaceutical distributor McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice (CD&R) reached an agreement on Tuesday to take infusion therapy provider Option Care Health (OPCH.O) private in a deal valued at approximately $5.8 billion, including debt. The acquisition price of $32.05 per share represents a 37.1% premium over Option Care's most recent closing price. The stock rose 33% in pre-market trading to $31.11. This deal, part of McKesson’s latest efforts to expand in healthcare services, marks another acquisition of a home healthcare provider by a private equity fund following the Enhabit deal. Option Care Health is the largest independent provider of infusion therapy in the US, serving over 308,000 patients annually through more than 197 service locations, offering home and outpatient infusions, specialty pharmacy services, and care for complex conditions. Demand for home healthcare in the US has been growing amid an aging population and as more patients opt for care outside of high-cost settings such as hospitals. After the deal closes, CD&R will hold the majority stake, while McKesson will own a minority stake. Option Care Health will continue to operate as an independent company, led by its own management team. Under the transaction terms, McKesson will invest about $1.4 billion for a 49% stake and retain the right to purchase the remaining 51% from CD&R at a later date. Leerink Partners analyst Michael Cherny noted in a report Monday evening that the deal aligns McKesson with the trend of shifting healthcare services away from hospitals and institutions. In addition, given McKesson’s operation of Canada’s leading infusion and injection network Inviva, the transaction expands its footprint in US home infusion services. McKesson’s oncology and multi-specialty business unit, which includes infusion services, generated revenue of $14.2 billion in the latest quarter, up 33% year-over-year, driven by specialty drug distribution and contributions from acquisitions. The deal is expected to close in the first half of 2027, after which Option Care Health will become a private company.